Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 16/20 | 0.71 |
| ▸ | GPR183 | P32249 | 1/20 | 0.46 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.37 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19454550 | 0.89 | GPR119 (0.68) | GPR119GPR183CNR2KCNH2 | |
| SCHEMBL19455007 | 0.87 | GPR119 (0.55) | GPR119GPR183ALOX5APLMNAMAPT | |
| SCHEMBL11956913 | 0.87 | GPR119 (0.68) | GPR119GPR183CNR2KCNH2LMNA | |
| SCHEMBL14895589 | 0.86 | GPR119 (0.64) | GPR119GPR183CNR2KCNH2LMNA | |
| SCHEMBL1103887 | 0.86 | GPR119 (0.64) | GPR119GPR183CNR2KCNH2LMNA | |
| SCHEMBL28725071 | 0.85 | GPR119 (0.67) | GPR119GPR183CNR2KCNH2LMNA | |
| SCHEMBL6118208 | 0.85 | GPR119 (0.67) | GPR119GPR183CNR2KCNH2LMNA | |
| SCHEMBL1922450 | 0.84 | GPR119 (0.65) | GPR119GPR183CNR2KCNH2 | |
| SCHEMBL19450515 | 0.84 | GPR119 (0.65) | GPR119GPR183ALOX5APCNR2KCNH2 | |
| SCHEMBL470543 | 0.84 | GPR119 (0.73) | GPR119GPR183CNR2KCNH2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3440087-B1 | THIAZOLOPYRIDINE DERIVATIVES AS GPR119 AGONISTS | MANKIND PHARMA LTD (IN) | 2022-08-10 | — | — | EP | disclosed |
| CN-109415381-B | Thiazolopyridine derivatives as GPR119 agonists | 人类制药有限公司 | 2022-03-25 | — | — | CN | disclosed |
| US-10919915-B2 | Compounds as GPR119 agonists | MANKIND PHARMA LTD. (IN) | 2021-02-16 | — | — | US | disclosed |
| US-10919915-B2 | Compounds as GPR119 agonists | MANKIND PHARMA LTD. (IN) | 2021-02-16 | — | — | US | disclosed |
| US-10723699-B2 | Cyclohexene derivative, preparation method thereof, and pharmaceutical composition for preventing or treating metabolic disease comprising the same as active ingredient | HYUNDAI PHARM CO., LTD. (KR) | 2020-07-28 | — | — | US | disclosed |
| US-10723699-B2 | Cyclohexene derivative, preparation method thereof, and pharmaceutical composition for preventing or treating metabolic disease comprising the same as active ingredient | HYUNDAI PHARM CO., LTD. (KR) | 2020-07-28 | — | — | US | disclosed |
| EP-3138834-B1 | CYCLOHEXENE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING METABOLIC DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT | HYUNDAI PHARM CO LTD (KR) | 2020-03-04 | — | — | EP | disclosed |
| EP-3138834-B1 | CYCLOHEXENE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING METABOLIC DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT | HYUNDAI PHARM CO LTD (KR) | 2020-03-04 | — | — | EP | disclosed |
| US-20200040006-A1 | NOVEL COMPOUNDS AS GPR119 AGONISTS | MANKIND PHARMA LTD. (IN) | 2020-02-06 | — | — | US | disclosed |
| US-20200040006-A1 | NOVEL COMPOUNDS AS GPR119 AGONISTS | MANKIND PHARMA LTD. (IN) | 2020-02-06 | — | — | US | disclosed |
| US-20110224185-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC, a Delaware Limited Company (BM) | 2011-09-15 | — | — | US | disclosed |
| US-20110224185-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC, a Delaware Limited Company (BM) | 2011-09-15 | — | — | US | disclosed |
| EP-2325182-A1 | Bicyclic compounds and use as antidiabetics | Glaxosmithkline LLC (US) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010103333-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2010-09-16 | — | — | WO | disclosed |
| US-20100029650-A1 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | SMITH KLINE BEECHAM CORPORATION a corporation | 2010-02-04 | — | — | US | disclosed |
| US-20090270409-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2009-10-29 | — | — | US | disclosed |
| US-20090270409-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2009-10-29 | — | — | US | disclosed |
| EP-2094683-A2 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | SmithKline Beecham Corporation (US) | 2009-09-02 | — | — | EP | disclosed |
| WO-2009038974-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2009-03-26 | — | — | WO | disclosed |
| WO-2008070692-A2 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224185-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | GPR119, GPR65, GPR39 | GPR119 1/4885GPR183 20/4885ALOX5AP 943/4885 |
| US-20200040006-A1 | NOVEL COMPOUNDS AS GPR119 AGONISTS | GPR119, GPR84, GPR65 | GPR119 1/4885GPR183 19/4885ALOX5AP 836/4885 |
| US-20090270409-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | GPR119, GPR65, GPR39 | GPR119 1/4885GPR183 20/4885ALOX5AP 943/4885 |
| US-10723699-B2 | Cyclohexene derivative, preparation method thereof, and pharmaceutical composition for preventing or treating metabolic disease comprising the same as active ingredient | GPR119, GLP1R, GCGR | GPR119 1/4885GPR183 19/4885ALOX5AP 2264/4885 |
| US-10919915-B2 | Compounds as GPR119 agonists | GPR119, GPR84, GPR65 | GPR119 1/4885GPR183 18/4885ALOX5AP 704/4885 |
| US-20100029650-A1 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | GPR119, GOT2, PC | GPR119 1/4885GPR183 1491/4885ALOX5AP 2945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.